Navigation Links
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Date:5/10/2013

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.  LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).

The pioneer phase of the study was designed to gain important initial information regarding the safety of co-administration of LX4211 with insulin in this, the first test of dual inhibition of SGLT1 and SGLT2 in patients with insulin-dependent type 1 diabetes.  The successful conclusion of the 28-day pioneer group enables the initiation of the placebo-controlled expansion phase of the study to commence in up to 30 patients with type 1 diabetes.  Based on the results observed in the pioneer group, Lexicon has identified the 400 mg once daily dose of LX4211 as the appropriate treatment for the expansion phase of the trial.

"This is a very important first step in the future development of LX4211 in type 1 diabetes," said Dr. Arthur Sands , president and chief executive officer of Lexicon. "The preliminary results are very encouraging and provide a strong rationale for moving into the expansion phase of the trial."

LX4211, a first-in-class dual inhibitor, reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. Lexicon has previously demonstrated that SGLT1 inhibition by LX4211 incre
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
(Date:9/22/2014)... , Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... scheduled to present a corporate overview and update at ... September 26, 2014, at 11:30 a.m. Eastern Time (8:30 ... New York City . ... available under the investor relations section of Arena,s website ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... Researchers have found that environment has a much ... a severe, often painful food allergy that renders ... foods. , Eosinophils are normal cellular components ... too many eosinophils they can cause a variety ... inflammation and resulting tissue damage, often in the ...
(Date:9/22/2014)... surprise, it turned out to be an old acquaintance: ... has hitherto always been considered an anchor protein. The ... , Essential: importing enzymes into peroxisome ... degradation of long-chain fatty acids and cellular toxins. In ... enzymes have to be imported into the peroxisomes first. ...
(Date:9/22/2014)... Cancer Science Institute of Singapore (CSI Singapore) at ... an increase in a gene known as Leo1 ... acute myelogenous leukaemia (AML), increasing the incidence of ... Wee Joo, Deputy Director and Senior Principal Investigator ... University Cancer Institute, Singapore, the scientists discovered that ...
(Date:9/22/2014)... Texas (PRWEB) September 22, 2014 ... and treatment, will work with companies to help employees ... the development of diabetes as part of a collaboration ... Diabetes @ Work initiative. , PreDiabetes Centers Medical ... Department of Transportation in Austin on Tuesday, October 21st ...
(Date:9/22/2014)... 22, 2014 The invitation only ... attended by 60 industry executives and thought leaders ... International, GoodLife, Retro Fitness, and Xsport Fitness. Also ... retention and marketing agencies and private equity investors ... gym members. , The Summit highlighted best practices ...
Breaking Medicine News(10 mins):Health News:Environment plays bigger role than genetics in food allergic disease eosinophilic esophagitis 2Health News:The accelerator of molecular motors 2Health News:Singapore researchers discover a gene that increases incidence of AML 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... chief of Renal Medicine and director of the Nephrology ... of medicine at Boston University School of Medicine (BUSM) ... Castle Connolly Medical Ltd. , The America,s Top Doctors ... a trusted and authoritative resource for identifying top doctors ...
... To improve the quality of the rapidly expanding array ... entered into a Memorandum of Understanding (MOU) with the ... for Biological Standards and Control (NIBSC) of the United ... plants or animals, rather than those created in a ...
... related to quality of marriage relationship, , , THURSDAY, Dec. ... poorer outcomes for women with breast cancer, a new ... in troubled marriages had higher levels of stress, less ... of illness than women who reported good marriages. ...
... men with chronic prostatitis, a painful disorder of the ... symptoms in recently diagnosed men who had not been ... trial sponsored by the National Institute of Diabetes and ... Institutes of Health (NIH). The study is to be ...
... Society has worked out new guidelines for the diagnosis ... Malignant melanoma is responsible for 90% of deaths from ... last 30 years and UV radiation is thought to ... , Claus Garbe of Tbingen University and his ...
... time with kids is one option to consider , , THURSDAY, ... be important considerations when you,re looking for children,s Christmas gifts, ... Philadelphia. , "Parents often feel like they have to ... chairman and professor of occupational therapy, said in a university ...
Cached Medicine News:Health News:Marital Distress May Affect Breast Cancer Recovery 2Health News:Common treatment for chronic prostatitis fails to reduce symptoms 2Health News:'Hot' Toys May Not Be the Best Present 2
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: